Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Better outcomes were achieved with combinations of experimental new drugs targeting common and rare tumour mutations.
Annual screening is now recommended for current and former smokers ages 50 to 80, regardless of whether they quit.
Tumor-treating fields therapy uses electricity delivered via a wearable device to kill cancer cells.
Responders may be able to discontinue immune checkpoint inhibitors after two years with no decrease in survival.
Models based on personal risk may be more useful than those based on age and smoking history alone.
Treatment has shifted to immunotherapy, but survival gains have been small for people over age 75.
Targeted therapies can reduce the size and number of brain metastases; patients could then have better-tolerated radiation therapy.
People treated with a durvalumab-based regimen before and after surgery had a 32% lower risk of disease recurrence or progression.
Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.
Combination therapy that includes a novel antibody is superior to immunotherapy alone for advanced non-small-cell lung cancer.
Screening is recommended for current and former heavy smokers ages 50 to 80, but HIV-positive people may benefit from earlier screening.
Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.
Emotions play a powerful role in living with cancer, a truth AJ Patel learned a decade ago when he was diagnosed with metastatic lung cancer
Although most people screened meet the USPSTF criteria, only one in five returned for a follow-up test a year later.
The checkpoint inhibitor is now approved for people with advanced non-small-cell lung cancer regardless of PD-L1 biomarker levels.
However, lung cancer incidence among HIV-positive people has fallen over the past two decades.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.